SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Imagin Medical Inc. (IMEXF)

IMEXF RSS Feed
Add IMEXF Price Alert      Hide Sticky   Hide Intro
Moderator: SO75, jb1965
Search This Board: 
Last Post: 7/22/2017 10:45:29 PM - Followers: 6 - Board type: Free - Posts Today: 0





 

 

Overview

 Imagin Medical is a medical imaging company
Imagin Medical will establish a new standard of care in the detection and removal of cancer using endoscopes by commercializing an advanced, proprietary and patented imaging technology
 Initially targeting bladder cancer 
 Thereafter expanding to all minimally invasive surgical (MIS) procedures where endoscopes are used
 

Benefits of Minimally Invasive Surgery (MIS)

• Performed using tiny holes or incisions (less muscle cut)
• Reduced pain, smaller / no scarring
• Quicker recovery, shorter hospital stay, less expensive
• Minimally invasive surgeries performed using endoscopes














 


Endoscopic Primer

• Endoscopic means “to look inside”
• Endoscope – a medical device with attached light used to look inside organs
• Endoscopy performed when other tools, such as an MRI, X-ray, or CT scan, are inappropriate
• Endoscopies commonly performed to diagnose cancer, take tissue samples for biopsies, and to remove cancer
• Different medical specialties use different types of endoscopes
• Cystoscopes, Bronchoscopes, Gastroscopes, Laparoscopes
   










 

Endoscopic Market
 
 $46B growing global endoscopy market
 $1B is spent annually in US alone on bladder cancer surveillance
 Bladder cancer is 3rd most common in men and 6th most common in US overall with recurrence rate of 40 – 70% making it the most expensive cancer to treat over the lifetime of a patient
 4 million estimated urology endoscopy procedures performed each year targeting bladder cancer
 Imagin’s disruptive imaging technology squarely addresses limitations in:
• Endoscopies targeting bladder cancer (cystoscopies)
• Endoscopies targeting many other cancers


 


 

Endoscope Limitations - White Light

• Current endoscopes use “white light” (or visible light) that has been the gold standard for decades
• Highly effective for detecting protruding cancerous tumors
• Limitations of white light:
• Tumors that are flat may look the same as normal tissue
• Not effective in visualizing the edges of the tumor
• Inability to illuminate tumors beneath skin surface


 

Endoscope Limitations - Blue Light

• Blue light cystoscopes (white light with blue filter) used with contrasting agents induce fluorescence and improve ability to detect flat cancers and visualize edges
• Drawbacks of existing blue light technology:
• Requires one hour for the agent to be absorbed by bladder
• Surgeon must manually “switch” between white light and blue light to see tumor area
• Repeated usage of imaging agent causes adverse side-effects (FDA limits use of contrast agents to one-time use per patient)
 

 
Disruptive Technology - Endoscopes with i/Blue Imaging System

• Significantly reduced prep time with bladder absorption in less than 15 minutes vs. one hour
• Optics 100,000 X more sensitive
• Simultaneous acquisition of differing images
• No switching back and forth
• Blends the white light and fluorescence images into one
• Enables the surgeon to better visualize and resect the cancer
• This advancement makes i/Blue technology practical, not only for the O.R. but also potentially for the physicians’ office
• Adapts seamlessly to most types of endoscopes on the market
 
Future Development - i/Vision Imaging System

• Incorporates multiple illumination sources in one system
• Accommodates the most commonly used fluorescing contrast agents, i.e., such as those based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG)
• This instrument enables expansion into multiple endoscopic procedures such as laparoscopic (general and gynecology), colorectal, thoracic and gastroenterology procedures related to cancer and non-cancerous conditions
• Like i/Blue, blends two images into one, adapts to most endoscopes, and orders of magnitude more sensitive
 
Future Development - i/Red Imaging System

• Requires no contrasting agents - uses the fluorescence produced by the body and tumor itself
• Contrast between normal and cancer tissue is potentially related to difference in porphyrin content within the cells
• Dramatically expands the market to endoscopic procedures where imaging agents cannot be practically administered
• Like i/Blue, blends two images into one, adapts to most endoscopes, orders of magnitude more sensitive
 
Intellectual Property

• Underpinning company’s technology are three issued patents and two pending patent applications on technology related to near-infrared spectroscopic imaging for cancer and other medical applications obtained, under exclusive license, from Lawrence Livermore National Security, LLC
• Aim of licensing agreement is to commercialize the technology invented by Dr. Stavros Demos, a key advisor to the company


 
Product Development Roadmap


 
Why Invest in Imagin Medical?

• Key investment risks removed, high investment return potential
• Disruptive cutting edge imaging technology will dramatically reduce bladder cancer recurrence rates addressing $1B growing global market
• Limited R&D risks as concept is proven – this is an execution play
• Experienced medical device management team that has done it before
• Management in medical device field for over 30 years
• Worked together in previous companies
• High-margin product with strong clinical and economic advantages
• Commercial launch expected in 2018 with positive operating cash flows
• Strong acquisition market
• Most medical device companies grow by acquisition, not organically
• Company expected to have significant value with multiple liquidity options
 

 
Number of Shares Outstanding as at June 30, 2017:                50,068,739
 
Shares Subject to Resale Restrictions    
1) Shares subject to escrow (1,725,000 released every 6 months - Feb 9 & Aug 9) 5,175,000  
2) Performance shares 5,000,000  
Total Shares Subject to Resale Restrictions   10,175,000
Total Tradeable Float   39,893,739
Total Shares Outstanding   50,068,739

Number of Warrants Outstanding as at June 30, 2017:             25,005,064
 
Warrants Outstanding    
Feb 2016 Private Placement Strike @ 0.35 - expire Feb 9, 2018 7,007,413
Q4/2016 PP - Tranche 1 Strike @ 0.12 / 0.16 - expire Oct 20, 2018 5,111,300
Q4/2016 PP - Tranche 2 Strike @ 0.12 / 0.16 - expire Dec 9, 2018 3,980,565
Warrants from BSS acquisition Strike @ 0.15 - expire Feb 9, 2019 8,905,786
Total Warrants Outstanding   25,005,064

Number of Options Outstanding as at June 30, 2017:                3,650,000
 
 Management Options Outstanding    
Tranche 1 Strike @ 0.12 300,000
Tranche 2 Strike @ 0.15 3,350,000
Total Options Outstanding   3,650,000
 
Various Company Links

Company Web Site
Corporate Presentation (4/1/2017)

CSE Web Site for Imagin Medical
SEDAR Web Site for Imagin Medical

Listing Statement CSE - February 16, 2016

Share Issuance - February 9, 2016
Share Issuance - August 22, 2016
Share Issuance - October 21, 2016
Share Issuance - December 13, 2016
Convertible Debt Issuance - March 3, 2016

Option Grant - June 30, 2016
Option Grant - December 19, 2016
Option Grant - April 10, 2017

Information Circular - October 31, 2016

Monthly CSE Filings (CSE Form 7)
 
  2016 2017
January N/A Link
February Link Link
March Link Link
April Link Link
May Link Link
June Link Link
July Link  
August Link  
September Link  
October Link  
November Link  
December Link  

Financial Statements (FS) & Management Discussion and Analyses (MD&A)
 
      2015 2016 2017
Q2 Quarter Ended March 31 FS   Link Link
MD&A   Link Link
Q3 Quarter Ended June 30 FS   Link  
MD&A   Link  
Q4 Quarter Ended September 30 FS Link Link  
MD&A Link Link  
Q1 Quarter Ended December 31 FS Link Link  
MD&A Link Link  

 

 
IMEXF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#175  Sticky Note An update to the Human Clinical Trial Timeline jb1965 07/22/17 10:45:28 PM
#175   An update to the Human Clinical Trial Timeline jb1965 07/22/17 10:45:28 PM
#174   Are we dead yet? jesse 07/05/17 10:06:33 AM
#173   Strong Q3 and Q4 ahead. The stock price SO75 06/28/17 12:49:17 PM
#172   Good to see this corporate update... jb1965 06/28/17 12:05:01 PM
#171   Both in time. SO75 06/01/17 08:13:49 AM
#170   how? will they do a pp? or use hoyowasobo 06/01/17 03:04:36 AM
#169   Financial Austerity jb1965 05/31/17 05:43:59 PM
#168   34,073 cash according to the latest financial statement. hoyowasobo 05/31/17 03:39:07 PM
#167   I don't worry about the crazy micro trades. 7Card 05/20/17 01:32:13 AM
#166   Like you are going to do anything productive teq0904 05/17/17 03:33:15 PM
#165   Ya but now I have answers SO75 05/17/17 03:26:55 PM
#164   Good idea for everyone to tie them all teq0904 05/17/17 03:22:38 PM
#163   Can someone explain how this stock drops to SO75 05/17/17 09:38:23 AM
#162   Perfect time to accumulate more or jump in. This SO75 05/17/17 06:45:25 AM
#161   Continuing to tread sideways between support and resistance. jb1965 05/16/17 11:56:19 PM
#158   I don't believe so. Some of their doctors jb1965 05/16/17 06:07:05 PM
#157   I saw Dr Messing. But it doesn't seem SO75 05/16/17 06:06:44 PM
#156   Interesting I was not aware of this. Are the presenting SO75 05/16/17 05:40:47 PM
#155   Today is the last day of the AUA jb1965 05/16/17 05:35:35 PM
#154   yes..I think we should all call and email SO75 05/16/17 05:13:43 PM
#153   An update on where things currently stand would jb1965 05/16/17 05:07:59 PM
#152   Monthly CSE Report SO75 05/03/17 12:57:36 PM
#151   I'm speaking period. Not just one particular stock AMG 05/01/17 05:38:13 PM
#150   I haven't changed my mind..it just hasn't dropped SO75 05/01/17 04:47:17 PM
#148   Yeah...until one changes their mind. I mean "Spidey AMG 05/01/17 03:54:52 PM
#147   Hey 7Card, there's a couple ways to shell3 04/28/17 08:02:08 AM
#146   shell3 how did you find out about the MD&A? 7Card 04/28/17 03:00:25 AM
#145   MD&A filed today shell3 04/27/17 10:21:58 PM
#144   No BTH IME is a winner SO75 04/26/17 05:44:57 PM
#143   Was your spidey senses tickling comment in reference jb1965 04/26/17 05:43:48 PM
#142   Nope..have to pass on that other one. See SO75 04/26/17 02:36:32 PM
#141   SO75 I'll be here. AMG 04/25/17 11:39:49 PM
#140   Imagin will revolutionize early cancer detection. 7Card 04/24/17 02:55:52 PM
#138   Bill Galine does the nr and is a teq0904 04/22/17 02:30:02 PM
#137   http://www.bnn.ca/sec-targets-fake-stock-news-on-financial-websites-1.720512 SO75 04/21/17 02:50:25 PM
#136   You're asking the wrong person. I have not AMG 04/21/17 02:20:50 AM
#135   So what are the pump sites you are 7Card 04/21/17 02:07:35 AM
#134   Imagin That AMG 04/19/17 07:57:33 PM
#133   I'll be here. Might be back at another board SO75 04/19/17 07:43:33 PM
#132   SO75 This is why I appreciate this company. AMG 04/19/17 07:36:39 PM
#131   890 West Pender Street, Suite 600 SO75 04/11/17 07:46:09 PM
#130   Thanks for this info update SO75. I never 7Card 04/11/17 01:29:37 AM
#129   NR's aren't done by the ir guy. 7Card 04/11/17 01:25:43 AM
#128   This is why I appreciate this company. SO75 04/10/17 01:34:13 PM
#127   Nothing anyone can do who doesn't work there. teq0904 04/08/17 06:10:02 PM
#126   Perhaps you could offer up your wisdom... jb1965 04/08/17 05:51:05 PM
#125   Nice SO75, thanks for this... jb1965 04/08/17 05:44:28 PM
#124   Also the start date of trials has been SO75 04/08/17 04:20:42 PM
#123   These might have been from insiders. They may SO75 04/08/17 04:16:56 PM
#122   The ir guy is a dinosaur who doesn't teq0904 04/08/17 03:04:49 PM
PostSubject